Arcotech Biopharma

Acrotech Biopharma is a U.S.-based specialty pharmaceutical company focused on developing and commercializing proprietary branded medicines, primarily in oncology and dermatology. Founded in 2018, the company was created as a platform within the Aurobindo group and entered branded oncology through the 2019 acquisition of a portfolio of marketed Spectrum products. Its current marketed portfolio includes Beleodaq, Khapzory, and Ryzneuta, and in 2026 it received FDA approval for Adquey (difamilast) for mild-to-moderate atopic dermatitis. Acrotech combines in-licensing, lifecycle management, internal development, and commercial infrastructure to expand branded products in the U.S. while working with partners for ex-U.S. markets. The company appears to be fully commercial-stage rather than a discovery-stage biotech.